MILESTONE PHARMACEUTICALS INC.

Analyst Reco. Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
1.38 ^USD	-0.72%		-2.13%	-17.37%

06-20	Transcript : Milestone Pharmaceuticals Inc. - Special Call
05-29	Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating	03-05	MT
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating	12-27	MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating	23-08-11	MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy	23-06-20	MT
Oppenheimer Adjusts Milestone Pharmaceuticals' Price Target to $13 From $16, Keeps Outperform Rating	23-04-12	MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $16 From $15, Maintains Outperform Rating	22-04-25	MT
Piper Sandler Lifts Milestone Pharmaceuticals to Overweight From Neutral, Price Target to $10 From $8	22-04-22	MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $14 From $17, Maintains Outperform Rating	21-05-18	MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $17 From $18 Following Q4 Report, Maintains Outperform Rating	21-03-31	MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate	21-03-29	MT
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate	21-03-29	CI
MILESTONE PHARMACEUTICALS : HC Wainwright Starts Milestone Pharmaceuticals at Buy With $20 Price Target	21-03-05	MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 3 Study of Etripamil Nasal Spray for Rapid Heart Rate	20-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer